SOL-1 is the first registrational trial for AXPAXLI™ in wet AMD Topline clinical data from SOL-1 expected in Q4 2025 Active ...

Researchers at Massachusetts Eye and Ear developed a preclinical research proof of concept that shows mRNA-based therapies ...

I’ve been eagerly anticipating a Medik8 Black Friday sale and, thankfully, my wish has been granted – there are indeed some ...

A new preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a ...

Campus Chemical Instrument Center, Mass Spectrometry & Proteomics Facility, The Ohio State University, Columbus, USA ...

A new study found that a novel mRNA-based therapy that targets a protein called RUNX1 may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR), a disease caused by a ...

In this new analysis, the Company reported changes in plasma biomarkers that may reflect Alzheimer's disease pathology. The results demonstrated that individuals who entered the study with plasma ...

Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery -- Multiple Events at Asia-Pacific ...

Myopia in children is on the rise. The condition – also known as shortsightedness – already affects up to 35% of children ...

The "Diabetes - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Diabetes - Pipeline Insight, 2024" report provides comprehensive insights about 200+ ...

Belite Bio's, Tinlarebant, targets eye diseases STGD1 and GA, showing promising results but with delayed phase 3 trial data.

Laser photocoagulation is a type of laser surgery for the eyes. It's done to treat age-related macular degeneration (AMD). AMD can lead to vision loss. The retina is the layer of nerve cells in the ...